Method
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.93% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTNEKTAR THERAPEUTICS's latest supported as-filed period reports revenue of $10.1M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.93% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value -747.90% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value -9.34% · CORE
Level · gp.fundamentals.operating_margin
Raw value -417.94% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 386.23% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 33.21% · OPTIONAL
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents decreased 8.7%; Operating cash flow decreased 65.7%.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Shares outstanding increased 79.5%; SBC / revenue moved 202 bp higher.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure increased 154.1%; Capex / revenue moved 60 bp higher.
2 evidence-backed componentsFree-cash-flow proxy changed -65.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
NKTR · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001213900-26-098042SEC ↗4Aug 20, 2026Period Aug 18, 20260001193125-26-359588SEC ↗4Aug 20, 2026Period Aug 18, 20260001193125-26-359586SEC ↗10-QAug 14, 2026Period Jun 30, 20260001193125-26-349805SEC ↗8-KAug 13, 2026Period Aug 13, 20260001213900-26-089137SEC ↗4Jul 24, 2026Period Jul 24, 20260001193125-26-316458SEC ↗4Jul 24, 2026Period Jul 24, 20260001193125-26-316457SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 18, 2026Filed Aug 20, 2026 | Zalevsky JonathanChief R&D Officer | Open Market SaleDirect | 186 | $72 | $13,388 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating cash flow changed -65.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current assets changed +296.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital changed +480.3% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Total assets changed +427.7% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Current ratio changed +298.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating margin changed -9373 basis points from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-295112